Alliance for Pandemic Preparedness

March 2, 2021

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021

Category:

Topic:

Keywords (Tags):

  • The Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the single-dose Johnson & Johnson COVID-19 vaccine in persons at least 18 years. The February 28, 2021 recommendation was based on a transparent evidence-based review of all available data, primarily informed by the interim analysis of the Phase 3 clinical trials including approximately 40,000 participants and reporting a 66% vaccine efficacy against symptomatic SARS-CoV-2 infection occurring at least 14 days after vaccination. Overall vaccine efficacy against hospitalization 14 days after immunization was 93% (CI= 71.1-98.4%) and no participant who was vaccinated was hospitalized 28 days after immunization. 

Oliver et al. (Mar 2, 2021). The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021. MMWR. Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm7009e4